• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    GE HealthCare Technologies (GEHC) Rises On Earnings Beat, But Is The Valuation Opportunity Still There

    Simply Wall St·07/29/2026 21:19:44
    Listen to the news

    GE HealthCare Technologies (GEHC) drew investor focus after reporting second quarter 2026 earnings in line with its previously raised guidance, along with a new long term Catholic Health partnership and a planned CFO transition.

    See our latest analysis for GE HealthCare Technologies.

    After the earnings release, GE HealthCare Technologies’ share price gained 4.89% on the day to $64.11. The 90 day share price return of 7.78% contrasts with a year to date share price decline of 22.59% and a 1 year total shareholder return that is down 17.35%, suggesting recent momentum has picked up after a weaker stretch.

    If this earnings move has you thinking about opportunities linked to medical imaging and diagnostics, it could be a useful moment to look at other healthcare AI stocks via our screener, including the 40 healthcare AI stocks.

    GE HealthCare Technologies now trades at a clear discount to both analyst targets and some intrinsic value estimates after this earnings pop. Is that simply market caution around execution and leadership changes, or a mispricing worth unpacking next?

    Most Popular Narrative: 19.6% Undervalued

    Against the last close of $64.11, the most followed narrative pegs GE HealthCare Technologies at a fair value of $79.72, implying meaningful upside in that framework.

    The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins. The focus on expanding recurring revenue, particularly in areas like digital solutions and advanced visualization, is expected to contribute positively to revenue stability and net margins.

    Read the complete narrative.

    Curious what justifies that higher fair value for GE HealthCare Technologies? The narrative leans on steady revenue expansion, rising margins, and a future earnings multiple that differs from today. The detailed path from current earnings to that outlook is where the story gets interesting.

    Result: Fair Value of $79.72 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, GE HealthCare Technologies still faces tariff and China regulatory risks, along with competitive pressure in imaging and diagnostics that could challenge this undervaluation story.

    Find out about the key risks to this GE HealthCare Technologies narrative.

    Next Steps

    With both risks and rewards in play for GE HealthCare Technologies, it makes sense to look at the full picture and move quickly to form your own view using the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond GE HealthCare Technologies?

    If this GE HealthCare Technologies update has sharpened your thinking, do not stop here. Use the tools available to quickly compare other potential opportunities side by side.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.